+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Pharmaceutical Market In Denmark 2026-2030

  • PDF Icon

    Report

  • 217 Pages
  • November 2026
  • Region: Denmark
  • TechNavio
  • ID: 5945937
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The pharmaceutical market in denmark is forecasted to grow by USD 855.5 mn during 2025-2030, accelerating at a CAGR of 3.4% during the forecast period. The report on the pharmaceutical market in denmark provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by demographic shifts and chronic disease burden, biopharmaceutical innovation and targeted therapies, ai and modernized digital clinical infrastructures.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.

The pharmaceutical market in denmark is segmented as below:

By Class Type

  • Musculoskeletal system
  • Nervous system
  • Respiratory system
  • Others

By Distribution Channel

  • Offline
  • Online

By Type

  • Prescription drugs
  • OTC drugs

By Drug Class

  • Branded drugs
  • Generic drugs

By Sector

  • Primary sector
  • Hospital sector

Geography

  • Europe
  • Denmark
This study identifies the supply chain resilience and manufacturing localization as one of the prime reasons driving the pharmaceutical market in denmark growth during the next few years. Also, specialty pharmaceuticals and rare disease therapies and combination products and smart drug delivery systems will lead to sizable demand in the market.

The report on the pharmaceutical market in denmark covers the following areas:

  • Pharmaceutical market in denmark sizing
  • Pharmaceutical market in denmark forecast
  • Pharmaceutical market in denmark industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading pharmaceutical market in denmark vendors that include AbbVie Inc., ALK Abello AS, Amgen Inc., AstraZeneca Plc, Bavarian Nordic AS, Bayer AG, Boehringer Ingelheim GmbH, Bristol Myers Squibb Co., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Ferring BV, FUJIFILM Holdings Corp., Genmab AS, H. Lundbeck AS, LEO Pharma AS, Novartis AG, Novo Nordisk AS, Pfizer Inc., Takeda Pharmaceutical Ltd., Zealand Pharma. Also, the pharmaceutical market in denmark analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary
1.1 Market overview
  • Executive Summary - Chart on Market Overview
  • Executive Summary - Data Table on Market Overview
  • Executive Summary - Chart on Country Market Characteristics
  • Executive Summary - Chart on Market Segmentation by Class Type
  • Executive Summary - Chart on Market Segmentation by Distribution Channel
  • Executive Summary - Chart on Market Segmentation by Type
  • Executive Summary - Chart on Market Segmentation by Drug Class
  • Executive Summary - Chart on Market Segmentation by Sector
  • Executive Summary - Chart on Company Market Positioning
2 Market Analysis
2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
2.2 Criticality of inputs and Factors of differentiation
  • Overview on criticality of inputs and factors of differentiation
2.3 Factors of disruption
  • Overview on factors of disruption
2.4 Impact of drivers and challenges
  • Impact of drivers and challenges in 2025 and 2030
3 Market Landscape
3.1 Market ecosystem
  • Chart on Parent Market
  • Data Table on - Parent Market
3.2 Market characteristics
  • Chart on Market characteristics analysis
3.3 Value chain analysis
  • Chart on Value chain analysis
4 Market Sizing
4.1 Market definition
  • Data Table on Offerings of companies included in the market definition
4.2 Market segment analysis
  • Market segments
4.3 Market size 2025
4.4 Market outlook: Forecast for 2025-2030
  • Chart on Denmark - Market size and forecast 2025-2030 ($ million)
  • Data Table on Denmark - Market size and forecast 2025-2030 ($ million)
  • Chart on Denmark: Year-over-year growth 2025-2030 (%)
  • Data Table on Denmark: Year-over-year growth 2025-2030 (%)
5 Historic Market Size
5.1 Pharmaceutical Market in Denmark 2020 - 2024
  • Historic Market Size - Data Table on Pharmaceutical Market in Denmark 2020 - 2024 ($ million)
5.2 Class Type segment analysis 2020 - 2024
  • Historic Market Size - Class Type Segment 2020 - 2024 ($ million)
5.3 Distribution Channel segment analysis 2020 - 2024
  • Historic Market Size - Distribution Channel Segment 2020 - 2024 ($ million)
5.4 Type segment analysis 2020 - 2024
  • Historic Market Size - Type Segment 2020 - 2024 ($ million)
5.5 Drug Class segment analysis 2020 - 2024
  • Historic Market Size - Drug Class Segment 2020 - 2024 ($ million)
5.6 Sector segment analysis 2020 - 2024
  • Historic Market Size - Sector Segment 2020 - 2024 ($ million)
6 Qualitative Analysis
6.1 Impact of AI on Pharmaceutical Market in Denmark
6.2 Impact of Geopolitical Conflicts on Pharmaceutical Market in Denmark
7 Five Forces Analysis
7.1 Five forces summary
  • Five forces analysis - Comparison between 2025 and 2030
7.2 Bargaining power of buyers
  • Bargaining power of buyers - Impact of key factors 2025 and 2030
7.3 Bargaining power of suppliers
  • Bargaining power of suppliers - Impact of key factors in 2025 and 2030
7.4 Threat of new entrants
  • Threat of new entrants - Impact of key factors in 2025 and 2030
7.5 Threat of substitutes
  • Threat of substitutes - Impact of key factors in 2025 and 2030
7.6 Threat of rivalry
  • Threat of rivalry - Impact of key factors in 2025 and 2030
7.7 Market condition
  • Chart on Market condition - Five forces 2025 and 2030
8 Market Segmentation by Class Type
8.1 Market segments
  • Chart on Class Type - Market share 2025-2030 (%)
  • Data Table on Class Type - Market share 2025-2030 (%)
8.2 Comparison by Class Type
  • Chart on Comparison by Class Type
  • Data Table on Comparison by Class Type
8.3 Musculoskeletal system - Market size and forecast 2025-2030
  • Chart on Musculoskeletal system - Market size and forecast 2025-2030 ($ million)
  • Data Table on Musculoskeletal system - Market size and forecast 2025-2030 ($ million)
  • Chart on Musculoskeletal system - Year-over-year growth 2025-2030 (%)
  • Data Table on Musculoskeletal system - Year-over-year growth 2025-2030 (%)
8.4 Nervous system - Market size and forecast 2025-2030
  • Chart on Nervous system - Market size and forecast 2025-2030 ($ million)
  • Data Table on Nervous system - Market size and forecast 2025-2030 ($ million)
  • Chart on Nervous system - Year-over-year growth 2025-2030 (%)
  • Data Table on Nervous system - Year-over-year growth 2025-2030 (%)
8.5 Respiratory system - Market size and forecast 2025-2030
  • Chart on Respiratory system - Market size and forecast 2025-2030 ($ million)
  • Data Table on Respiratory system - Market size and forecast 2025-2030 ($ million)
  • Chart on Respiratory system - Year-over-year growth 2025-2030 (%)
  • Data Table on Respiratory system - Year-over-year growth 2025-2030 (%)
8.6 Others - Market size and forecast 2025-2030
  • Chart on Others - Market size and forecast 2025-2030 ($ million)
  • Data Table on Others - Market size and forecast 2025-2030 ($ million)
  • Chart on Others - Year-over-year growth 2025-2030 (%)
  • Data Table on Others - Year-over-year growth 2025-2030 (%)
8.7 Market opportunity by Class Type
  • Market opportunity by Class Type ($ million)
  • Data Table on Market opportunity by Class Type ($ million)
9 Market Segmentation by Distribution Channel
9.1 Market segments
  • Chart on Distribution Channel - Market share 2025-2030 (%)
  • Data Table on Distribution Channel - Market share 2025-2030 (%)
9.2 Comparison by Distribution Channel
  • Chart on Comparison by Distribution Channel
  • Data Table on Comparison by Distribution Channel
9.3 Offline - Market size and forecast 2025-2030
  • Chart on Offline - Market size and forecast 2025-2030 ($ million)
  • Data Table on Offline - Market size and forecast 2025-2030 ($ million)
  • Chart on Offline - Year-over-year growth 2025-2030 (%)
  • Data Table on Offline - Year-over-year growth 2025-2030 (%)
9.4 Online - Market size and forecast 2025-2030
  • Chart on Online - Market size and forecast 2025-2030 ($ million)
  • Data Table on Online - Market size and forecast 2025-2030 ($ million)
  • Chart on Online - Year-over-year growth 2025-2030 (%)
  • Data Table on Online - Year-over-year growth 2025-2030 (%)
9.5 Market opportunity by Distribution Channel
  • Market opportunity by Distribution Channel ($ million)
  • Data Table on Market opportunity by Distribution Channel ($ million)
10 Market Segmentation by Type
10.1 Market segments
  • Chart on Type - Market share 2025-2030 (%)
  • Data Table on Type - Market share 2025-2030 (%)
10.2 Comparison by Type
  • Chart on Comparison by Type
  • Data Table on Comparison by Type
10.3 Prescription drugs - Market size and forecast 2025-2030
  • Chart on Prescription drugs - Market size and forecast 2025-2030 ($ million)
  • Data Table on Prescription drugs - Market size and forecast 2025-2030 ($ million)
  • Chart on Prescription drugs - Year-over-year growth 2025-2030 (%)
  • Data Table on Prescription drugs - Year-over-year growth 2025-2030 (%)
10.4 OTC drugs - Market size and forecast 2025-2030
  • Chart on OTC drugs - Market size and forecast 2025-2030 ($ million)
  • Data Table on OTC drugs - Market size and forecast 2025-2030 ($ million)
  • Chart on OTC drugs - Year-over-year growth 2025-2030 (%)
  • Data Table on OTC drugs - Year-over-year growth 2025-2030 (%)
10.5 Market opportunity by Type
  • Market opportunity by Type ($ million)
  • Data Table on Market opportunity by Type ($ million)
11 Market Segmentation by Drug Class
11.1 Market segments
  • Chart on Drug Class - Market share 2025-2030 (%)
  • Data Table on Drug Class - Market share 2025-2030 (%)
11.2 Comparison by Drug Class
  • Chart on Comparison by Drug Class
  • Data Table on Comparison by Drug Class
11.3 Branded drugs - Market size and forecast 2025-2030
  • Chart on Branded drugs - Market size and forecast 2025-2030 ($ million)
  • Data Table on Branded drugs - Market size and forecast 2025-2030 ($ million)
  • Chart on Branded drugs - Year-over-year growth 2025-2030 (%)
  • Data Table on Branded drugs - Year-over-year growth 2025-2030 (%)
11.4 Generic drugs - Market size and forecast 2025-2030
  • Chart on Generic drugs - Market size and forecast 2025-2030 ($ million)
  • Data Table on Generic drugs - Market size and forecast 2025-2030 ($ million)
  • Chart on Generic drugs - Year-over-year growth 2025-2030 (%)
  • Data Table on Generic drugs - Year-over-year growth 2025-2030 (%)
11.5 Market opportunity by Drug Class
  • Market opportunity by Drug Class ($ million)
  • Data Table on Market opportunity by Drug Class ($ million)
12 Market Segmentation by Sector
12.1 Market segments
  • Chart on Sector - Market share 2025-2030 (%)
  • Data Table on Sector - Market share 2025-2030 (%)
12.2 Comparison by Sector
  • Chart on Comparison by Sector
  • Data Table on Comparison by Sector
12.3 Primary sector - Market size and forecast 2025-2030
  • Chart on Primary sector - Market size and forecast 2025-2030 ($ million)
  • Data Table on Primary sector - Market size and forecast 2025-2030 ($ million)
  • Chart on Primary sector - Year-over-year growth 2025-2030 (%)
  • Data Table on Primary sector - Year-over-year growth 2025-2030 (%)
12.4 Hospital sector - Market size and forecast 2025-2030
  • Chart on Hospital sector - Market size and forecast 2025-2030 ($ million)
  • Data Table on Hospital sector - Market size and forecast 2025-2030 ($ million)
  • Chart on Hospital sector - Year-over-year growth 2025-2030 (%)
  • Data Table on Hospital sector - Year-over-year growth 2025-2030 (%)
12.5 Market opportunity by Sector
  • Market opportunity by Sector ($ million)
  • Data Table on Market opportunity by Sector ($ million)
13 Customer Landscape
13.1 Customer landscape overview
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
14 Drivers, Challenges, and Opportunity
14.1 Market drivers
  • Demographic shifts and chronic disease burden
  • Biopharmaceutical innovation and targeted therapies
  • AI and modernized digital clinical infrastructures
14.2 Market challenges
  • Regulatory divergence and compliance complexity
  • Pricing pressures and reimbursement barriers
  • Research and development attrition and patent expirations
14.3 Impact of drivers and challenges
  • Impact of drivers and challenges in 2025 and 2030
14.4 Market opportunities
  • Supply chain resilience and manufacturing localization
  • Specialty pharmaceuticals and rare disease therapies
  • Combination products and smart drug delivery systems
15 Competitive Landscape
15.1 Overview
15.2 Competitive Landscape
  • Overview on criticality of inputs and factors of differentiation
15.3 Landscape disruption
  • Overview on factors of disruption
15.4 Industry risks
  • Impact of key risks on business
16 Competitive Analysis
16.1 Companies profiled
  • Companies covered
16.2 Company ranking index
  • Company ranking index
16.3 Market positioning of companies
  • Matrix on companies position and classification
16.4 AbbVie Inc.
  • AbbVie Inc. - Overview
  • AbbVie Inc. - Business segments
  • AbbVie Inc. - Key news
  • AbbVie Inc. - Key offerings
  • AbbVie Inc. - Segment focus
  • SWOT
16.5 ALK Abello AS
  • ALK Abello AS - Overview
  • ALK Abello AS - Product / Service
  • ALK Abello AS - Key offerings
  • SWOT
16.6 AstraZeneca Plc
  • AstraZeneca Plc - Overview
  • AstraZeneca Plc - Business segments
  • AstraZeneca Plc - Key news
  • AstraZeneca Plc - Key offerings
  • AstraZeneca Plc - Segment focus
  • SWOT
16.7 Bavarian Nordic AS
  • Bavarian Nordic AS - Overview
  • Bavarian Nordic AS - Product / Service
  • Bavarian Nordic AS - Key offerings
  • SWOT
16.8 Bayer AG
  • Bayer AG - Overview
  • Bayer AG - Business segments
  • Bayer AG - Key news
  • Bayer AG - Key offerings
  • Bayer AG - Segment focus
  • SWOT
16.9 Bristol Myers Squibb Co.
  • Bristol Myers Squibb Co. - Overview
  • Bristol Myers Squibb Co. - Product / Service
  • Bristol Myers Squibb Co. - Key news
  • Bristol Myers Squibb Co. - Key offerings
  • SWOT
16.10 Eli Lilly and Co.
  • Eli Lilly and Co. - Overview
  • Eli Lilly and Co. - Product / Service
  • Eli Lilly and Co. - Key news
  • Eli Lilly and Co. - Key offerings
  • SWOT
16.11 F. Hoffmann La Roche Ltd.
  • F. Hoffmann La Roche Ltd. - Overview
  • F. Hoffmann La Roche Ltd. - Business segments
  • F. Hoffmann La Roche Ltd. - Key news
  • F. Hoffmann La Roche Ltd. - Key offerings
  • F. Hoffmann La Roche Ltd. - Segment focus
  • SWOT
16.12 FUJIFILM Holdings Corp.
  • FUJIFILM Holdings Corp. - Overview
  • FUJIFILM Holdings Corp. - Business segments
  • FUJIFILM Holdings Corp. - Key news
  • FUJIFILM Holdings Corp. - Key offerings
  • FUJIFILM Holdings Corp. - Segment focus
  • SWOT
16.13 Genmab AS
  • Genmab AS - Overview
  • Genmab AS - Product / Service
  • Genmab AS - Key offerings
  • SWOT
16.14 H. Lundbeck AS
  • H. Lundbeck AS - Overview
  • H. Lundbeck AS - Product / Service
  • H. Lundbeck AS - Key offerings
  • SWOT
16.15 Novartis AG
  • Novartis AG - Overview
  • Novartis AG - Business segments
  • Novartis AG - Key news
  • Novartis AG - Key offerings
  • Novartis AG - Segment focus
  • SWOT
16.16 Novo Nordisk AS
  • Novo Nordisk AS - Overview
  • Novo Nordisk AS - Business segments
  • Novo Nordisk AS - Key offerings
  • Novo Nordisk AS - Segment focus
  • SWOT
16.17 Pfizer Inc.
  • Pfizer Inc. - Overview
  • Pfizer Inc. - Business segments
  • Pfizer Inc. - Key news
  • Pfizer Inc. - Key offerings
  • Pfizer Inc. - Segment focus
  • SWOT
16.18 Zealand Pharma
  • Zealand Pharma - Overview
  • Zealand Pharma - Product / Service
  • Zealand Pharma - Key offerings
  • SWOT
17 Appendix
17.1 Scope of the report
  • Market definition
  • Objectives
  • Notes and caveats
17.2 Inclusions and exclusions checklist
  • Inclusions checklist
  • Exclusions checklist
17.3 Currency conversion rates for US$
  • Currency conversion rates for US$
17.4 Research methodology
  • Research methodology
17.5 Data procurement
  • Information sources
17.6 Data validation
  • Data validation
17.7 Validation techniques employed for market sizing
  • Validation techniques employed for market sizing
17.8 Data synthesis
  • Data synthesis
17.9 360 degree market analysis
  • 360 degree market analysis
17.10 List of abbreviations
  • List of abbreviations
List of Exhibits
Exhibit 1: Executive Summary - Chart on Market Overview
Exhibit 2: Executive Summary - Data Table on Market Overview
Exhibit 3: Executive Summary - Chart on Country Market Characteristics
Exhibit 4: Executive Summary - Chart on Market Segmentation by Class Type
Exhibit 5: Executive Summary - Chart on Market Segmentation by Distribution Channel
Exhibit 6: Executive Summary - Chart on Market Segmentation by Type
Exhibit 7: Executive Summary - Chart on Market Segmentation by Drug Class
Exhibit 8: Executive Summary - Chart on Market Segmentation by Sector
Exhibit 9: Executive Summary - Chart on Company Market Positioning
Exhibit 10: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibit 11: Overview on criticality of inputs and factors of differentiation
Exhibit 12: Overview on factors of disruption
Exhibit 13: Impact of drivers and challenges in 2025 and 2030
Exhibit 14: Chart on Parent Market
Exhibit 15: Data Table on - Parent Market
Exhibit 16: Chart on Market characteristics analysis
Exhibit 17: Chart on Value chain analysis
Exhibit 18: Data Table on Offerings of companies included in the market definition
Exhibit 19: Market segments
Exhibit 20: Chart on Denmark - Market size and forecast 2025-2030 ($ million)
Exhibit 21: Data Table on Denmark - Market size and forecast 2025-2030 ($ million)
Exhibit 22: Chart on Denmark: Year-over-year growth 2025-2030 (%)
Exhibit 23: Data Table on Denmark: Year-over-year growth 2025-2030 (%)
Exhibit 24: Historic Market Size - Data Table on Pharmaceutical Market in Denmark 2020 - 2024 ($ million)
Exhibit 25: Historic Market Size - Class Type Segment 2020 - 2024 ($ million)
Exhibit 26: Historic Market Size - Distribution Channel Segment 2020 - 2024 ($ million)
Exhibit 27: Historic Market Size - Type Segment 2020 - 2024 ($ million)
Exhibit 28: Historic Market Size - Drug Class Segment 2020 - 2024 ($ million)
Exhibit 29: Historic Market Size - Sector Segment 2020 - 2024 ($ million)
Exhibit 30: Five forces analysis - Comparison between 2025 and 2030
Exhibit 31: Bargaining power of buyers - Impact of key factors 2025 and 2030
Exhibit 32: Bargaining power of suppliers - Impact of key factors in 2025 and 2030
Exhibit 33: Threat of new entrants - Impact of key factors in 2025 and 2030
Exhibit 34: Threat of substitutes - Impact of key factors in 2025 and 2030
Exhibit 35: Threat of rivalry - Impact of key factors in 2025 and 2030
Exhibit 36: Chart on Market condition - Five forces 2025 and 2030
Exhibit 37: Chart on Class Type - Market share 2025-2030 (%)
Exhibit 38: Data Table on Class Type - Market share 2025-2030 (%)
Exhibit 39: Chart on Comparison by Class Type
Exhibit 40: Data Table on Comparison by Class Type
Exhibit 41: Chart on Musculoskeletal system - Market size and forecast 2025-2030 ($ million)
Exhibit 42: Data Table on Musculoskeletal system - Market size and forecast 2025-2030 ($ million)
Exhibit 43: Chart on Musculoskeletal system - Year-over-year growth 2025-2030 (%)
Exhibit 44: Data Table on Musculoskeletal system - Year-over-year growth 2025-2030 (%)
Exhibit 45: Chart on Nervous system - Market size and forecast 2025-2030 ($ million)
Exhibit 46: Data Table on Nervous system - Market size and forecast 2025-2030 ($ million)
Exhibit 47: Chart on Nervous system - Year-over-year growth 2025-2030 (%)
Exhibit 48: Data Table on Nervous system - Year-over-year growth 2025-2030 (%)
Exhibit 49: Chart on Respiratory system - Market size and forecast 2025-2030 ($ million)
Exhibit 50: Data Table on Respiratory system - Market size and forecast 2025-2030 ($ million)
Exhibit 51: Chart on Respiratory system - Year-over-year growth 2025-2030 (%)
Exhibit 52: Data Table on Respiratory system - Year-over-year growth 2025-2030 (%)
Exhibit 53: Chart on Others - Market size and forecast 2025-2030 ($ million)
Exhibit 54: Data Table on Others - Market size and forecast 2025-2030 ($ million)
Exhibit 55: Chart on Others - Year-over-year growth 2025-2030 (%)
Exhibit 56: Data Table on Others - Year-over-year growth 2025-2030 (%)
Exhibit 57: Market opportunity by Class Type ($ million)
Exhibit 58: Data Table on Market opportunity by Class Type ($ million)
Exhibit 59: Chart on Distribution Channel - Market share 2025-2030 (%)
Exhibit 60: Data Table on Distribution Channel - Market share 2025-2030 (%)
Exhibit 61: Chart on Comparison by Distribution Channel
Exhibit 62: Data Table on Comparison by Distribution Channel
Exhibit 63: Chart on Offline - Market size and forecast 2025-2030 ($ million)
Exhibit 64: Data Table on Offline - Market size and forecast 2025-2030 ($ million)
Exhibit 65: Chart on Offline - Year-over-year growth 2025-2030 (%)
Exhibit 66: Data Table on Offline - Year-over-year growth 2025-2030 (%)
Exhibit 67: Chart on Online - Market size and forecast 2025-2030 ($ million)
Exhibit 68: Data Table on Online - Market size and forecast 2025-2030 ($ million)
Exhibit 69: Chart on Online - Year-over-year growth 2025-2030 (%)
Exhibit 70: Data Table on Online - Year-over-year growth 2025-2030 (%)
Exhibit 71: Market opportunity by Distribution Channel ($ million)
Exhibit 72: Data Table on Market opportunity by Distribution Channel ($ million)
Exhibit 73: Chart on Type - Market share 2025-2030 (%)
Exhibit 74: Data Table on Type - Market share 2025-2030 (%)
Exhibit 75: Chart on Comparison by Type
Exhibit 76: Data Table on Comparison by Type
Exhibit 77: Chart on Prescription drugs - Market size and forecast 2025-2030 ($ million)
Exhibit 78: Data Table on Prescription drugs - Market size and forecast 2025-2030 ($ million)
Exhibit 79: Chart on Prescription drugs - Year-over-year growth 2025-2030 (%)
Exhibit 80: Data Table on Prescription drugs - Year-over-year growth 2025-2030 (%)
Exhibit 81: Chart on OTC drugs - Market size and forecast 2025-2030 ($ million)
Exhibit 82: Data Table on OTC drugs - Market size and forecast 2025-2030 ($ million)
Exhibit 83: Chart on OTC drugs - Year-over-year growth 2025-2030 (%)
Exhibit 84: Data Table on OTC drugs - Year-over-year growth 2025-2030 (%)
Exhibit 85: Market opportunity by Type ($ million)
Exhibit 86: Data Table on Market opportunity by Type ($ million)
Exhibit 87: Chart on Drug Class - Market share 2025-2030 (%)
Exhibit 88: Data Table on Drug Class - Market share 2025-2030 (%)
Exhibit 89: Chart on Comparison by Drug Class
Exhibit 90: Data Table on Comparison by Drug Class
Exhibit 91: Chart on Branded drugs - Market size and forecast 2025-2030 ($ million)
Exhibit 92: Data Table on Branded drugs - Market size and forecast 2025-2030 ($ million)
Exhibit 93: Chart on Branded drugs - Year-over-year growth 2025-2030 (%)
Exhibit 94: Data Table on Branded drugs - Year-over-year growth 2025-2030 (%)
Exhibit 95: Chart on Generic drugs - Market size and forecast 2025-2030 ($ million)
Exhibit 96: Data Table on Generic drugs - Market size and forecast 2025-2030 ($ million)
Exhibit 97: Chart on Generic drugs - Year-over-year growth 2025-2030 (%)
Exhibit 98: Data Table on Generic drugs - Year-over-year growth 2025-2030 (%)
Exhibit 99: Market opportunity by Drug Class ($ million)
Exhibit 100: Data Table on Market opportunity by Drug Class ($ million)
Exhibit 101: Chart on Sector - Market share 2025-2030 (%)
Exhibit 102: Data Table on Sector - Market share 2025-2030 (%)
Exhibit 103: Chart on Comparison by Sector
Exhibit 104: Data Table on Comparison by Sector
Exhibit 105: Chart on Primary sector - Market size and forecast 2025-2030 ($ million)
Exhibit 106: Data Table on Primary sector - Market size and forecast 2025-2030 ($ million)
Exhibit 107: Chart on Primary sector - Year-over-year growth 2025-2030 (%)
Exhibit 108: Data Table on Primary sector - Year-over-year growth 2025-2030 (%)
Exhibit 109: Chart on Hospital sector - Market size and forecast 2025-2030 ($ million)
Exhibit 110: Data Table on Hospital sector - Market size and forecast 2025-2030 ($ million)
Exhibit 111: Chart on Hospital sector - Year-over-year growth 2025-2030 (%)
Exhibit 112: Data Table on Hospital sector - Year-over-year growth 2025-2030 (%)
Exhibit 113: Market opportunity by Sector ($ million)
Exhibit 114: Data Table on Market opportunity by Sector ($ million)
Exhibit 115: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibit 116: Impact of drivers and challenges in 2025 and 2030
Exhibit 117: Overview on criticality of inputs and factors of differentiation
Exhibit 118: Overview on factors of disruption
Exhibit 119: Impact of key risks on business
Exhibit 120: Companies covered
Exhibit 121: Company ranking index
Exhibit 122: Matrix on companies position and classification
Exhibit 123: AbbVie Inc. - Overview
Exhibit 124: AbbVie Inc. - Business segments
Exhibit 125: AbbVie Inc. - Key news
Exhibit 126: AbbVie Inc. - Key offerings
Exhibit 127: AbbVie Inc. - Segment focus
Exhibit 128: SWOT
Exhibit 129: ALK Abello AS - Overview
Exhibit 130: ALK Abello AS - Product / Service
Exhibit 131: ALK Abello AS - Key offerings
Exhibit 132: SWOT
Exhibit 133: AstraZeneca Plc - Overview
Exhibit 134: AstraZeneca Plc - Business segments
Exhibit 135: AstraZeneca Plc - Key news
Exhibit 136: AstraZeneca Plc - Key offerings
Exhibit 137: AstraZeneca Plc - Segment focus
Exhibit 138: SWOT
Exhibit 139: Bavarian Nordic AS - Overview
Exhibit 140: Bavarian Nordic AS - Product / Service
Exhibit 141: Bavarian Nordic AS - Key offerings
Exhibit 142: SWOT
Exhibit 143: Bayer AG - Overview
Exhibit 144: Bayer AG - Business segments
Exhibit 145: Bayer AG - Key news
Exhibit 146: Bayer AG - Key offerings
Exhibit 147: Bayer AG - Segment focus
Exhibit 148: SWOT
Exhibit 149: Bristol Myers Squibb Co. - Overview
Exhibit 150: Bristol Myers Squibb Co. - Product / Service
Exhibit 151: Bristol Myers Squibb Co. - Key news
Exhibit 152: Bristol Myers Squibb Co. - Key offerings
Exhibit 153: SWOT
Exhibit 154: Eli Lilly and Co. - Overview
Exhibit 155: Eli Lilly and Co. - Product / Service
Exhibit 156: Eli Lilly and Co. - Key news
Exhibit 157: Eli Lilly and Co. - Key offerings
Exhibit 158: SWOT
Exhibit 159: F. Hoffmann La Roche Ltd. - Overview
Exhibit 160: F. Hoffmann La Roche Ltd. - Business segments
Exhibit 161: F. Hoffmann La Roche Ltd. - Key news
Exhibit 162: F. Hoffmann La Roche Ltd. - Key offerings
Exhibit 163: F. Hoffmann La Roche Ltd. - Segment focus
Exhibit 164: SWOT
Exhibit 165: FUJIFILM Holdings Corp. - Overview
Exhibit 166: FUJIFILM Holdings Corp. - Business segments
Exhibit 167: FUJIFILM Holdings Corp. - Key news
Exhibit 168: FUJIFILM Holdings Corp. - Key offerings
Exhibit 169: FUJIFILM Holdings Corp. - Segment focus
Exhibit 170: SWOT
Exhibit 171: Genmab AS - Overview
Exhibit 172: Genmab AS - Product / Service
Exhibit 173: Genmab AS - Key offerings
Exhibit 174: SWOT
Exhibit 175: H. Lundbeck AS - Overview
Exhibit 176: H. Lundbeck AS - Product / Service
Exhibit 177: H. Lundbeck AS - Key offerings
Exhibit 178: SWOT
Exhibit 179: Novartis AG - Overview
Exhibit 180: Novartis AG - Business segments
Exhibit 181: Novartis AG - Key news
Exhibit 182: Novartis AG - Key offerings
Exhibit 183: Novartis AG - Segment focus
Exhibit 184: SWOT
Exhibit 185: Novo Nordisk AS - Overview
Exhibit 186: Novo Nordisk AS - Business segments
Exhibit 187: Novo Nordisk AS - Key offerings
Exhibit 188: Novo Nordisk AS - Segment focus
Exhibit 189: SWOT
Exhibit 190: Pfizer Inc. - Overview
Exhibit 191: Pfizer Inc. - Business segments
Exhibit 192: Pfizer Inc. - Key news
Exhibit 193: Pfizer Inc. - Key offerings
Exhibit 194: Pfizer Inc. - Segment focus
Exhibit 195: SWOT
Exhibit 196: Zealand Pharma - Overview
Exhibit 197: Zealand Pharma - Product / Service
Exhibit 198: Zealand Pharma - Key offerings
Exhibit 199: SWOT
Exhibit 200: Inclusions checklist
Exhibit 201: Exclusions checklist
Exhibit 202: Currency conversion rates for US$
Exhibit 203: Research methodology
Exhibit 204: Information sources
Exhibit 205: Data validation
Exhibit 206: Validation techniques employed for market sizing
Exhibit 207: Data synthesis
Exhibit 208: 360 degree market analysis
Exhibit 209: List of abbreviations

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • AbbVie Inc.
  • ALK Abello AS
  • Amgen Inc.
  • AstraZeneca Plc
  • Bavarian Nordic AS
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Bristol Myers Squibb Co.
  • Eli Lilly and Co.
  • F. Hoffmann La Roche Ltd.
  • Ferring BV
  • FUJIFILM Holdings Corp.
  • Genmab AS
  • H. Lundbeck AS
  • LEO Pharma AS
  • Novartis AG
  • Novo Nordisk AS
  • Pfizer Inc.
  • Takeda Pharmaceutical Ltd.
  • Zealand Pharma